Novo and Sanofi are among the investors that could exit Yale's mineralisation disease therapy developer, which has filed to raise up to $86.3m.
Inozyme Pharma, a US-based mineralisation disorder drug spinout of Yale University, has filed for an $86.3m initial public offering on the Nasdaq Global Market.
Founded in 2015, Inozyme is targeting on rare, debilitating diseases caused by abnormal mineralisation and affecting soft tissue, the vascular system and the skeleton.
The company’s lead asset, INZ-701, aims to correct deficiencies in pathways responsible for conditions such as generalised arterial calcification of infancy, a disorder with symptoms including heart failure, difficulty…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
